DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Ciprofibrate

Ciprofibrate

  • Full Text

    Full Text

  • Joint Assessment Report Was Discussed by the Phvwp at Its Meeting in July 2007 and Finalised in September 2007

    Joint Assessment Report Was Discussed by the Phvwp at Its Meeting in July 2007 and Finalised in September 2007

  • PI Changes for Fibrates

    PI Changes for Fibrates

  • Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number

    Fenofibrate, Bezafibrate, Ciprofibrate and Gemfibrozil Procedure Number

  • Methods of Chromatographic Determination of Medicines Decreasing the Level of Cholesterol

    Methods of Chromatographic Determination of Medicines Decreasing the Level of Cholesterol

  • Update of Comparative Effectiveness of Lipid-Modifying Agents

    Update of Comparative Effectiveness of Lipid-Modifying Agents

  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL

    Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL

  • Estonian Statistics on Medicines 2013 1/44

    Estonian Statistics on Medicines 2013 1/44

  • Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

    Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

  • Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to “Mother Teresa” University Hospital in Albania

    Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to “Mother Teresa” University Hospital in Albania

  • Review of Existing Classification Efforts

    Review of Existing Classification Efforts

  • Study Protocol 1002-046 Amendment 1, 10 April 2017

    Study Protocol 1002-046 Amendment 1, 10 April 2017

  • Cholesterol-Interacting Layered Phyllosilicates for Suppressing Gastrointestinal Cholesterol Absorption

    Cholesterol-Interacting Layered Phyllosilicates for Suppressing Gastrointestinal Cholesterol Absorption

  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……

    Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……

  • FAMILIAL HYPERCHOLESTEROLAEMIA (Based on NICE Clinical Guideline 71, Last Updated Oct 2019)

    FAMILIAL HYPERCHOLESTEROLAEMIA (Based on NICE Clinical Guideline 71, Last Updated Oct 2019)

  • Lipid Lowering: Another Method of Reducing Blood Pressure?

    Lipid Lowering: Another Method of Reducing Blood Pressure?

  • 1. NAME of the MEDICINAL PRODUCT Fluvastatin 20 Mg / 40

    1. NAME of the MEDICINAL PRODUCT Fluvastatin 20 Mg / 40

  • The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS- 2 Cov-2 in Cell Culture Models

    The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS- 2 Cov-2 in Cell Culture Models

Top View
  • Ciprofibrate 100Mg Tablets
  • Antidiabetic Action of Bezafibrate in a Large Observational Database
  • ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
  • (12) United States Patent (10) Patent No.: US 6,696,084 B2 Pace Et Al
  • A Review on Anti-Cholesterol Drugs and Their Mechanisms
  • Lipid Management in Patients with Endocrine Disorders: an Endocrine
  • 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
  • Prevention of Murine Atherosclerosis with Bempedoic Acid
  • Technology Road Mapping for Innovation Pathways of Fibrates: a Cross-Database Patent Review
  • Disease Agonists As Therapy for Autoimmune Α Peroxisome
  • PPAR-Mediated Toxicology and Applied Pharmacology
  • Accessibility Improving Information Using Online Patient Drug Reviews
  • New Product Highlights
  • Coadministration of Multidrug Therapy to Achieve Lipid Goals JAOA • Supplement 7 • Vol 104 • No 9 • September 2004 • S17 Drug Class Mechanism of Action
  • WO 2018/148417 Al 16 August 2018 (16.08.2018) W!P O PCT
  • Fenofibrate: a Novel Formulation (Triglide™) in the Treatment of Lipid Disorders: a Review
  • Proposed OPPTS Science Policy: PPAR-Alpha Mediated
  • ESC/EAS Guidelines for the Management of Dyslipidemias


© 2024 Docslib.org    Feedback